Buy at low point

If company still don't manage to growth , I think many investor will start loss confident.

Anyhow by current situation. Most probably counter need time to get recover only.

Nothing is impossible.

Kanger got news or got technical can play la. Long hold need to take own risk.
GP cannot la, Puan not steady. Consider G3 la. Puan just left the counter.
Something is brewing soon I guess

2021 many counter gg

Make sure having good enter point, then can heng ong huat aldi

heng ong huat

https://klse.i3investor.com/blogs/HIDDENGEMLIST/2021-11-04-story-h1593666375-Should_you_subscribe_to_ARB_BERHAD_s_rights_issue.jsp

Seems ok mate, Can enter mou ? I come to being greedy now.

In my opinion, any sell down or panic selling in ARBB shares in the upcoming trading days is an extremely good opportunity for investors to invest in the company. Personally, I aim for RM0.50 as my TP in the midterm post rights issue.

Suzhou MedicalSystem had connections with approximately 80% of China’s triple-A Grade hospitals.

For the investment savvies, the JV will require a total initial capex of RMB5.0 million, which RMB4.05 million will be coming from BIOHLDG and the rest to be paid by Suzhou MedicalSystem. This would translate to an 81% stake in the Suzhou BioMedic. Apart from that, the company would also inject Intellectual Properties (IPs) into the Suzhou Biomedic including formulations that aid Type 2 Diabetes and for those who are undergoing Hormone Replacement Therapy (HRT) as well.

Actually from the article above, we can see that bholding is doing the best to transform their company to more strong fundamental based. Instead of goreng, I guess they want to convert their business to a long run structure.

@alvinchua87

Back to Suzhou BioMedic, all the IPs that BIOHLDG that will be injecting into consists of immunity-boosting, obesity-care, anti-ageing, longevity as well as β-nicotinamide mononucleotide or NMN supplement. A study by Frost and Sullivan indicates that the market size for antidiabetic treatment in China is expected to grow with 12.2% CAGR from 2018 to 2027, where the HRT market in China is expected to grow with 4.6% CAGR from 2020 to 2027.

We do not know any guidance on the future earnings yet, but assuming the JV could contribute 50% of what Bioalpha Hainan is doing on a minimum case scenario, that would mean an additional revenue contribution of RM8.2 million per quarter and RM32.8 million per financial year. A conservative net profit margin of 12% would result in an increase of RM3.9 million in net profit and when translated to market capitalization with the 5-year average PER of 22.8 times, it is expected to add RM86.6 million to the market capitalization or 7.3 cents per share.

Unfortunately, due to the bad market condition, BIOHLDG’s price could not reflect its true value. Personally, I think BIOHLDG is worth at least 27 ~ 28 cents in value. We shall wait for the market to rebound and determine market’s assumption on the company valuation.

Anyhow today just discover a company venture to Solar business too. lmao

https://klse.i3investor.com/blogs/blogging2win/2021-09-23-story-h1571678877-Another_solar_related_gem_that_is_YET_to_be_discovered_by_investors.jsp

Is all about time

Relax guys, Cypark is still solid when come to Solar sector.

Nice, engine heated up, share price moving

well, if the no change ? Share price will fly ? hehee.. Time for goreng ?

https://www.theborneopost.com/2021/07/12/task-force-to-vaccinate-sabah-construction-workers/

KOTA KINABALU: The Construction Industry Vaccination Program (CIVac) will be extended to Sabah in the earliest possible future.


Dr Roland Chia Ming Shen, director of Construction Industry Development Board (CIDB) Malaysia, disclosed on Monday.

He said a special task force had been set up in Sabah to expedite CIVAc in Sabah. The task force will comprise of federal and state agencies and the stakeholders of the construction industry namely the developers, builders, professional consultants and hardware materials operators.

This is in line with the Federal Minister of Works and the Chief Minister of Sabah’s call to expedite the vaccination program for the construction industry in Sabah.

The Construction Industry Development Board Malaysia through CIDB Holdings Sdn Bhd (a wholly own subsidiary of CIDB Malaysia) which is an agency under the Federal Ministry of Works, has introduced the CIVac to accelerate the vaccination uptake among the construction workforce to achieve herd immunity and reduce the Covid-19 workplace clusters.

This program aims at protecting the well-being of employees in the construction industry and subsequently facilitate in expediting Malaysia’s economic recovery.

CIVac is to complement the National Covid-19 Immunisation Program (PICK).


Through CIVac, members of the industry in Sabah may register for the vaccination programme.

The vaccines are provided free of charge but the employers will need to pay for administrative cost of RM90 per person to cover the medical facilities and venue expenses as CIVac is a public-private initiative.

Besides, KANGER’s share price had bottomed at 5.5 cents recently and just rebounded to 6.5 cents, and I believe that was caused by the market refused to believe the vaccine story by KANGER.



Don’t you think, we should collect the share of KANGER during cheap times?



I rest my case.

Dated 27th May 2021, KANGER had also got into a MoU between the Sabah State Government to supply more doses of vaccine into the highest infected state in the country.



With investor’s concern on NPRA approval, don’t forget our country is faced with dilemma. A full month lock down again, do you think voters would vote them in the next upcoming GE? In their sweet dreams. Without a full initiative to speed up vaccination to recovery the economical activities, the politicians will definitely panic and therefore – the MoU of KANGER is most likely a go.



I understand that KANGER had several MoU previously and some of them had opted out – but bear in mind, this is with the state government, and I doubt they will toy around.

With that in mind, our government had opened more opportunities. Targeted to get 16 million more doses in the next two months, the government had allowed AstraZeneca vaccine to be used for those who volunteer. As an initiative opened by KANGER INTERNATIONAL BERHAD (KLSE:KANGER), which is currently a major bamboo player in the China region, our government had started to accept Sinopharm as one of the vaccines to be consumed.



As for Sinopharm, it had an approximate 79% effective rate based on China’s statistic. I would also like to point out that in 2020, China is the only country in the world with positive GDP growth. As Asian, China’s vaccine should be more compatible to us as compared to Western countries.

As sad as this sound, but with the mere progress of only 4.0% vaccinated out of 32 million Malaysians, we are getting nowhere to a full economical recovery. By comparison, our neighbour – Singapore had 6.2% vaccination rate. At this pace, we can no longer purely relying on Pfizer and Sinovac vaccine.

However, do you notice that our government never disclose the prices of the transaction of purchasing vaccine? That is because they signed an NDA with Pfizer and Sinovac – and I can tell you, the prices are not cheap.

https://klse.i3investor.com/blogs/hsb23/2021-06-13-story-h1566193431-A_Vaccine_Darling_That_You_Should_Include_in_Your_Portfolio.jsp

Kanger is small step toward the greatness

All same account only, just to spamming around. lazy to see all this fake and multiple account sure doing ramdom sharing in this group.

That few account more like same person. Both only active attack the counter.

Strong support at 0.65. which is a good sign to kick start tomorrow. Let see...

RIGHTS ISSUE WITH WARRANTS APPROVED! TIME TO FLY SOON?!

Seasoned investors that are familiar with corporate exercise would definitely be no stranger to rights issue. But for new investors, rights issue is commonly a way for listed companies to raise additional capital from shareholders – sometimes it also comes with a sweetener, warrant.


How impactful is warrant on the share price? Just take a look at these few companies share price after bonus issue or rights issue that comes with warrant.


Of course, there are plenty more examples where companies that issued free warrants might spike up. But why is that so?

Warrant – as a financial derivative which carries the ability to allow its holder to have the right but not obligated to convert it into mother share, often seen as an opportunity to arbitrage. It is an advanced technique that often used by seasoned investors but to put it in plain English, some big holders of warrant might “push” the mother share price to increase the attractiveness in warrant due to the conversion gap and the arbitrage opportunity.

However, Kanger International Berhad (KLSE: KANGER) – the recent darling of vaccine theme play had finally gotten their approval from Bursa for the rights issue that comes along with the warrant sweetener.

How do we know for sure KANGER might fly anytime soon? To answer this question, we must study the price movement pattern of the company.

As you can see, the company had a downturn in share price and momentum since the vaccine market was slammed hard by the government. But what we could tell from the chart is that there is an attempt to breakout on 28th May 2021. What could possibly trigger the buying momentum?

After going around several forums and platforms, I noticed that there are already rumours being spread on KANGER’s rights issue shall be approved at anytime soon. Perhaps this spiked the buying interest – but unfortunately, the company only announced the good news on yesterday, hence investors might have got in too early.

Nevertheless, with the approval for warrants, I’m sure that KANGER will continue to fly once operator had finished the accumulation of shares – which they already did since 2019 to 2020 and washed most new investors off KANGER by now.

From technical analysis + corporate news standpoint, we could begin our execution on the trade. The for-sure support level for the company is at 6.0 cents level. And the most recent resistance of the company would be at 11.5 cents and 15.0 cents, respectively. This represents a potential downside risk of 20.0%, and for the upside, that would be between 53.3% and 100.0%, representing a risk-to-reward ratio of 2.6 times to 5.0 times!

On the back of years of my trading experience, KANGER will definitely ride on the positive news and depart soon. Do not miss out the ride on this company!

Nice

price started to move

kanger seems strongest among all vaccine counter as in reputation, got chance to limit up soon ?

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

Kanger going to spike high to the sky, buy now with current discount price
expect to receive a shipment of Covid-19 vaccines in June 2021.

High Risk High return

Good timing to buying in.

Thanks @ucrst2140q

https://klse.i3investor.com/blogs/truthfinder2021/2021-03-24-story-h1542957382.jsp

结论： 目前为止，我们并没有方法来认定PEB是不是个骗局。 但是，我们可以根据公司所提供的公开信息以及对股份的一些常识判断， PEB的反向收购计划将会成功。 基于对最近的反向收购案例的研究与个人经验，我们以后一定没有机会在更便宜的价格入股，时机已过了，就没机会了。

话虽如此， 投资者们都没法预测反向收购的结果以及股价的变动。希望大家们理性分析并做出明智的投资决策。

第四个问题： 如果PEB是间好公司，那这是个无风险的投资吗？

我的观点： 这世界并没有所谓的无风险投资。 没风险的投资则肯定是个骗局。 现在投资PEB将面临多种风险,包括反向收购可能会失败，股价的波动以及交易流动性低。 当然，最大的风险仍然是反向收购是否可以通过。

在论坛上有些误导性的流言，流言提到说若反向收购在 2021 年 6 月时不获批准， PEB将会被马来西亚股票交易所除名。 在这里我想指出，上市公司可以延长反向收购所需的时间， 而且PEB属于一家 PN 16 公司，而不是PN 17 公司。 若反向收购被延迟了，作为净现金公司的 PN 16 公司无法被这样退市。

我认为一旦反向收购成功后，股价的波动性以及低流动性问题将被解决。让我们拭目以待吧。

第三个问题： 这家太阳能公司真的值钱吗？

我的观点： Rondy 先生在文章中指出， 将要被注入 PEB 的 reNikola 拥有3处已运行的太阳能厂，其总发电量为88 MWp。 在reNikola的官方网站上所提供的RAM报告已公布reNikola与TNB签订了购电协议，这在能源产业是很普遍的协议。

这证明了reNikola是一家正当营业的公司吗？

大家可能对于reNikola还没完成的330 MWp 黑木山发电厂有些疑问。 市场能消化那么多绿色能源吗？ reNikola的管理层已为此做好了准备，黑木山发电厂准备为大型企业提供能源。 想必读者们已经注意到越来越多的公司正在关注着ESG的发展。 这是其中一个基金管理的未来趋势，如果你希望基金购买你公司的股票，拥有ESG（环境、社会和公司治理）将是个优势。

第二个问题： PEB的估值问题， 现在PEB被高估了吗？

我的观点： 这确实是一个开放性问题。 我们先研究在2020年至2021年中成功进行反向收购的公司，LAGENDA, Kerjaya Prospek 和即将进行RTO的 GRANFLO的股价走势。 在反向收购刚开始时，股价波动持平， 但是股价都在短短的一至两年内平均增长了100%， 并实际上为投资者们带来了41.42％的复合增长率。

目前还能找得到拥有此优势的公司吗？ 这是当然的，如果你打算入股 PEB, 你目前的风险受到了限制。 理由在于公司持有者和PAC拥有公司 65.5% 的股份，因此当前的PEB股东都比你更关心股价！

那么PEB现在是被低估了还是被高估了？ 我对此没有正确的答案， 我们还是等待TA Securities 给我们正确的最终估值。

第一个问题： PEB的反向收购是炒作或炒股价吗？

我的观点： Ciruela Sdn. Bhd. 或其最大股东,Lim Beng Guan 和其 PAC 每股RM 1.07的价格收购了PEB 65.5%的股份。 这触发了强制性全面收购建议条例，并以 RM 1.07 的价格向其他的股东收购剩余的股份。

新股东们还以现金方式支付了约 RM 48.5m 的股份。 他们是否会为了炒股而花费了 RM 50m？ 对我来说， 没有什么是不可能的， 但是新股东们将如何出售暴涨后高达 65.5% 的股权呢？显而易见的，这是非常困难的。

因此，PEB的反向收购存在炒作因素的可能性甚低。

Keep on going !!!!!! Tp 2 , tp 2

Heavy sell down , lol

Not sure is a fake queue or not but I know is a discount time. Hehehe....

Topglove so dare to keep share buy back sure got reason behind de. Parking a bit come in first.

Why good company price will drop, it seems related with glove ?